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identiﬁed for study inclusion. Sildenaﬁl was the most common initial treatment (n = 
455 patients), followed by bosentan (n = 251 patients) and ambrisentan (n = 21 
patients). On average, ambrisentan patients received one pill/day with a daily dose of 
7 mg, bosentan patients received 2 pills/day with a daily dose of 222 mg, and sildenaﬁl 
patients received 2.3 pills/day with a daily dose of 61 mg. Approximately 44% of 
ambrisentan, 35% of bosentan, and 25% of sildenaﬁl patients experienced a dose 
increase (p = 0.013) during the follow-up period. PAH-related inpatient and emergency 
department utilization were similar among the groups, while ambulatory visits differed 
among the groups, with average monthly counts of 1.2, 0.8, and 0.5 visits for ambris-
entan, bosentan, and sildenaﬁl patients (p < 0.001). Follow-up total PAH-related costs 
were signiﬁcantly different among the groups, with average monthly costs of $6820, 
$5332, and $3632 for ambrisentan, bosentan, and sildenaﬁl patients (p = 0.020). Cost 
differences were primarily driven by PAH-related pharmacy costs, which were signiﬁ-
cantly lower in sildenaﬁl patients (p < 0.001). CONCLUSIONS: Of the three oral 
PAH treatments studied, sildenaﬁl was the most frequently prescribed, and was associ-
ated with lower pharmacy and overall costs than either ambrisentan or bosentan.
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IMPORTANT DISAGREEMENT BETWEEN MEASURES OF THE 
INTERNATIONAL NORMALIZED RATIO
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OBJECTIVES: The Bland-Altman method is often upheld as the optimal method to 
assess agreement between alternate measures of the same clinical parameter. However, 
recent research by our group demonstrates the Bland-Altman method does not report 
agreement in a clinically meaningful way. The objective was to determine if the Bland-
Altman method distinguished between two point-of-care (POC) INR devices. These 
devices were previously shown to have signiﬁcantly different levels of agreement with 
our core laboratory. METHODS: In a previous experiment, 170 patients provided 
three separate INR measures at the same clinic visit—two by POC (AvosureTM and 
ProTimeTM devices) and one venous sample analyzed at our core laboratory (consid-
ered the standard measure). Agreement was achieved when the POC and lab INR 
values led to the same clinical decision. Differences in agreement between the POC 
devices and laboratory were assessed by McNemar’s test. In the current study, we 
applied the Bland-Altman method to determine if inferences regarding agreement 
between the POCs and laboratory were identical to the previous experiment where 
clinical decisions deﬁned agreement. RESULTS: The Avosure device was signiﬁcantly 
more likely to lead to the same clinical decision as the laboratory versus the ProTime 
device (80% vs. 66%, respectively, p < 0.001). However, the Bland-Altman method 
produced virtually identical mean bias (0.4 and 0.5 INR units, respectively) and did 
not distinguish between the devices. Statistical analysis of the Bland-Altman method 
produced the same ﬁndings for each device: signiﬁcantly different standard deviations 
between the POC and the laboratory (p < 0.001), signiﬁcant bias in each device (p < 
0.001), and high correlations between the POCs and the laboratory (0.925 and 0.926, 
respectively). CONCLUSIONS: The Bland-Altman method did not detect clinically 
important differences between the POC INR devices. Clinically meaningful agreement 
between measures of INR is optimally assessed by a method that directly observes or 
explicitly estimates clinical decisions.
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OBJECTIVES: To determine the proportion of the post-surgery prophylaxis period 
that warfarin-treated patients undergoing total hip or total knee replacement (THR/
TKR) spent in the American College of Chest Physicians (ACCP)-recommended thera-
peutic international normalized ratio (INR) range using two methods: within-patient 
proportion and Rosendaal linear interpolation. METHODS: Using an electronic data-
base, patients undergoing total THR/TKR between January 1, 2004 and January 31, 
2009 who received warfarin within 3 days after surgery were identiﬁed and followed 
for up to 90 days. Analysis focused on Day 5 onward¯since warfarin takes several 
days to reach therapeutic effect¯and on patients with at least 2 measured INR levels 
during this period. INR results were categorized based on ACCP guidelines: in range 
(2–3), below range (<2), or above range (>3). The proportion of INR levels within 
each range was determined for each patient, and the distribution of these within-
patient proportions computed. Time within each range was imputed using the Rosend-
aal method, which assumes a linear interpolation between observed measurements, 
applying an INR level to each treatment day. RESULTS: A total of 653 THR and 871 
TKR patients were identiﬁed; both groups had a median of 5 INR measurements from 
Day 5. Median within-patient percentages of in-range INR values were 33% for the 
average THR patient and 29% for the average TKR patient. Using the Rosendaal 
method, THR patients spent a median 29% and TKR patients a median 28% of 
within-patient proportion of time within the INR 2–3 range. CONCLUSIONS: The 
within-patient proportion of actual INR values and the proportion of imputed days 
spent in the ACCP-recommended therapeutic range (2–3) were similar in this post-
surgical cohort of THR/TKR patients. Regardless of the method, the majority of INR 
values among all patients were outside of the ACCP-recommended INR therapeutic 
range.
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OBJECTIVES: To develop a methodology to link patients from two de-identiﬁed 
databases and leverage unique data from both to measure the impact of blood pressure 
and clinical ﬁndings on total costs. METHODS: Hypertensive patients (ICD-9 diag-
nosis 401.xx-405.xx) were identiﬁed from the MarketScan Commercial and Medicare 
Supplemental administrative claims databases (MarketScan) and the GE Centricity 
Electronic Medical Record (EMR) database (Centricity) for the years 2004–2008. A 
hybrid approach of deterministic and probabilistic matches was developed to identify 
common patients. Patients were included if they matched on zip code, gender and 
month of birth, and had at least three matching ofﬁce visit dates at a rate of 75% or 
higher. Patients were followed for 12 months after the initial diagnosis. MarketScan 
provided data on enrollment, all reimbursed services (medical and drug) and costs, 
and Centricity provided clinical and biometric details, such as body mass index (BMI) 
and blood pressure. RESULTS: Among the 3 million MarketScan and 1.5 million 
Centricity patients with hypertension, 31,786 met the matching criteria. Mean age 
was 58 and 54% were female. The demographic and clinical characteristics of these 
patients did not vary substantially from those of the two data sources. Among the 
31,786 patients, 84% received drug treatment, 56% had a BMI over 30 and mean 
systolic and diastolic values were 134 and 81, respectively. Mean unadjusted costs 
were $9,338 for patients with consistently controlled (ﬁrst and last systolic <140 and 
diastolic < 90) hypertension and $8,773 for patients not consistently controlled. 
CONCLUSIONS: A combined probabilistic and deterministic approach of linking 
patients yielded a sample size large enough to conduct a study and leverage the 
strengths of administrative and EMR data. Initial ﬁndings suggest that controlled 
patients incur higher costs, however, adjustments have not been made for additional 
demographic, clinical, and treatment characteristics.
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OBJECTIVES: Log models are widely used to deal with skewed outcomes, such as 
health care costs. They improve precision of estimates and diminish the inﬂuence of 
outliers. Smearing estimation suggested in literature only works with homoskedastic 
or heteroskedastic errors due to categorical variables. Generalized linear models 
(GLM) have been proposed as an alternative to deal with any kind of heteroskedastic-
ity but recent literature shows that log models are superior to GLM under certain 
conditions. We present a method using log transformation that accounts for any kind 
of heteroskedasticity in the estimation of health care cost METHODS: Assume there 
is a population represented by the random vector of explanatory variables (ex. patient 
and clinical characteristics) and with the scalar response variable (ex. health care costs) 
and we want to estimate unknown parameters. Assume that error terms are in function 
of explanatory variables, and therefore heteroskedasticity exists. By modeling hetero-
skedasticity separately, we created a weight function and using this weight in an 
outcomes model, we corrected the heteroskedasticity in the log transformed model. 
Retransformation was done by adjusting for heteroskedasticity. RESULTS: As a case 
study, we calculated the burden of illness of venous thromboembolism (VTE). The 
difference between the cost of VTE and non-VTE patients is estimated to be $6,345 
and $8,239 depending on whether the proposed or a GLM model is used. The stan-
dard errors changed signiﬁcantly depending on the model. The difference was signiﬁ-
cant with the log transformed model with heteroskedasticity-adjusted standard errors 
and the GLM model. However, the difference was insigniﬁcant when the adjustment 
was not done. CONCLUSIONS: Log transformation provides more efﬁcient estima-
tors than GLM models under certain conditions (ex. if there is excess kurtosis) and 
heteroskedasticity can be adjusted even if its form is unknown.
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BACKGROUND: Clinical trials frequently exclude patients likely to die within the 
trial timeframe. Thus, these highly-selected patients have lower initial mortality prob-
abilities relative to the age- and gender-matched general population. OBJECTIVES: 
To capture the effect that clinical trial exclusion criteria have on intermediate-term 
(i.e., one- to ﬁve-year) death probabilities in study subjects with substantial asymp-
tomatic carotid artery stenosis. METHODS: We “phased-in” certain relevant death 
probabilities in a microsimulation model using data from the Asymptomatic Carotid 
Atherosclerosis Study (ACAS). The phase-in process initially eliminates or greatly 
reduces the mortality probability from a condition (reﬂecting patients excluded with 
